The global urinary tract cancer market was valued at $1,704.5 million in 2020, and is estimated to reach $8,786.2 million by 2030, growing at a CAGR of 18.6% from 2021 to 2030.
Urinary tract cancer is the most common type of cancer found in urethra, bladder, and renal pelvic. Cystoscopy is the gold standard procedure for the diagnosis of bladder cancer. The other technology such as computed tomography (CT) urography is used for obtaining images of the upper tract in macroscopic hematuria. The exact etiology of urinary tract cancer is unknown, but prolonged indwelling bladder catheters, smoking, chronic inflammation in the urinary tract and exposure to carcinogenic chemicals, are the key factors which might develop urinary tract cancer.
Growth of the global urinary tract cancer market is majorly driven by an increase in prevalence of bladder cancer; rise in funding from private & government organizations for development of research centers; rise in growth of geriatric population; and increase in R&D activities in the healthcare sector. Bladder cancer is the 10th most common cancer, across the globe. For instance, according to American Cancer Society, in 2021, it was reported that around 83,730 population are diagnosed with bladder cancer, in the U.S. Moreover, the University investment and philanthropic donations funded $1.18 million to the bladder cancer research centers, which was launched in the University of Birmingham, in the UK. In addition, rise in geriatric population who are more vulnerable to bladder cancer fuels the market growth during the forecast period. The aging population are more prone to urinary tract cancer due to weakening of immune cells that fight against the cancer tissue in bladder. According to American society of clinical oncology (ASCO) organization, in January 2021, it was reported that around 90% of the people with bladder cancer are more than 55 year of age. Furthermore, according to American cancer society, 2019, it was observed that smoking along with workplace exposure can act together to cause bladder cancer. For instance, in August 2021, Merck, one of the leading global biopharmaceutical company, announced the U.S. Food and Drug Administrative approval for Keytruda (pembrolizumab), which is used for the treatment of Urothelial Carcinoma. Thus, the increasing number of approval for treatment of urinary tract cancer, and surge in sedentary life style such as smoking and rise in exposure to chemical industry propel the growth of the market. Moreover, the presence of highly specialist urologist for the treatment of cancer, and increase in number of cancer research centers.
However, risk associated with the use of drug prescribed for urinary tract cancer such as irritation in bladder, blood in urine, and infection is expected to restrict the market growth during the forecast period.
Urinary Tract Cancer Market Segmentation
The urinary tract cancer market is segmented on the basis of cancer type, treatment type, distribution channel, and region. By cancer type, the market is categorized into bladder cancer, urethral cancer, and ureteric and renal pelvic cancer.
By treatment type, the market is divided into chemotherapy, and immunotherapy. By distribution channel, the market is fragmented into retail pharmacy, and online pharmacy.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment review
Depending on cancer type, the bladder cancer segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in healthcare expenditure, advancement in available therapies, and increase in prevalence of bladder cancer. However, the ureteric and renal pelvic cancer segment is expected to witness considerable market growth during the forecast period, owing to increase in prevalence of renal pelvic cancer, availability of novel drugs and rise in geriatric population.
By Cancer Type
Bladder Cancer segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
On the basis of treatment type, the immunotherapy segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing increase in incidence of cancer, a rise in the number of approvals, stringent government regulation and increase in number of smokers. However, the chemotherapy segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of cancer, a rise in the geriatric population, development of advanced therapy, increase in the number of clinical trial study and advancement in cancer research center.
By Treatment Type
Immunotherapy segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
On the basis of distribution channel, the retail pharmacy consumers segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in number of hospital & oncology centers, rise in prevalence of cancer, surge in demand for prescribed drug, and rise in the number of drug approval for treatment of cancer. However, the online pharmacy segment is expected to witness considerable growth during the forecast period, owing to rise in prevalence of cancer, advancement in technology in healthcare sector, and rise in demand for remote monitoring service.
By Distribution Channel
Retail Pharmacy segment is projected as one of the most lucrative segment.
North America accounted for a major share in the urinary tract cancer market in 2020, and is expected to maintain its dominance during the forecast period, owing to rise in prevalence of bladder cancer, increase in healthcare expenditure, the presence of key players, availability of advanced therapy for cancer treatment, and advancement in R&D activities in healthcare sector in the region. However, Asia-Pacific is expected to register highest CAGR of 19.6% from 2021 to 2030, owing to increase in prevalence of urinary tract cancer, rise in the number of smoker, initiative taken by government and growing in number geriatric population.
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Key players operating in the global urinary tract cancer market include Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Endo International plc., Exelixis, Inc., GlaxoSmithKline Plc.(GSK), Merck KGAA, Novartis AG, Pfizer Inc., and Johnson & Johnson.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the urinary tract cancer market, and the current trends and future estimations to elucidate imminent investment pockets.
- It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Urinary Tract Cancer Market Report Highlights
| Aspects | Details |
 By Cancer type |
|
 By Treatment Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Eli Lily and Company, Exelixis, Inc., Johnson & Johnson, Endo International plc., GlaxoSmithKline Plc. (GSK), Astellas Pharma Inc., Bristol-Myers Squibb Company, Pfizer Inc., Merck KGAA, Novartis AG |
Analyst Review
Growth of the urinary tract cancer market is attributed to factors such as advancement in R&D activities in the healthcare sector; rise in prevalence of urinary tract cancer, such as bladder cancer; increase in funds from private and government organizations for various research centers, and rise in the geriatric population. The urinary tract cancer market gains interest of healthcare companies, owing to increase in number of approval of advanced therapies for treatment of urinary tract cancer. This leads to increase in adoption of urinary tract cancer diagnostic device and treatment therapy. Moreover, the increase in sedentary lifestyle, such as alcohol consumption, smoking, unhealthy diet, and prolong worker exposure to the chemical industry, who are more susceptible to urinary tract cancer are propelling the growth of the market.
Further, North America is expected to witness highest growth, in terms of revenue, owing to rise in prevalence of bladder cancer, an increase in healthcare expenditure, the presence of key players, availability of advanced therapy for cancer treatment, and advancement in R&D activities in healthcare sector in the region.
Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to increase in prevalence of urinary tract cancer, a rise in the number of smokers, initiatives taken by the government and increase in geriatric population.
In addition, risk associated with the use of the drug employed in urinary tract cancer such as irritation in bladder, blood in urine, and infection, is anticipated to restrain the market growth during the forecast period.
The total market value of urinary tract cancer market is $1,704.5 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of urinary tract cancer Market in 2021 was $1,888.6 million
The base year for the report is 2020.
Yes, urinary tract cancer companies are profiled in the report
The top companies that hold the market share in urinary tract cancer market are Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Endo International plc., Exelixis, Inc., GlaxoSmithKline Plc.(GSK), Merck KGAA, Novartis AG, Pfizer Inc., and Johnson & Johnson
No, there is no value chain analysis provided in the urinary tract cancer market report
The key trends in the urinary tract cancer market are by an alarming increase in the prevalence of bladder cancer, a rise in government initiative for prevention and treatment of bladder cancer, availability of advanced therapy, increase in number of approval of drugs, and rise in funds for R&D activities
Loading Table Of Content...
